Production of interleukin-1-receptor antagonist during experimental endotoxaemia

E. V. Granowitz, D. D. Poutsiaka, Joseph Gerard Cannon, S. M. Wolff, C. A. Dinarello, A. A. Santos, D. W. Wilmore

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

Interleukin-1 (IL-1) has been implicated in the pathogenesis of sepsis. IL-1-receptor antagonist (IL-1ra) is a naturally occurring inhibitor of IL-1 activity that competes with IL-1 for occupancy of cell-surface receptors but possesses no agonist activity. We induced endotoxaemia in 9 healthy human volunteers by injection of Escherichia coliendotoxin, and measured plasma concentrations of IL-1 and IL-1ra by radioimmunoassay during the next 24 h. Peak plasma concentrations of IL-1ra were about a hundred-fold greater than those of IL-1β. No IL-1 or IL-1ra were detectable in the plasma of 4 volunteers injected with saline. Our results suggest that the predominant natural response to endotoxin in man is the production of antagonist rather than agonist.

Original languageEnglish (US)
Pages (from-to)1423-1424
Number of pages2
JournalThe Lancet
Volume338
Issue number8780
DOIs
StatePublished - Dec 7 1991

Fingerprint

Endotoxemia
Interleukin-1 Receptors
Interleukin-1
Escherichia
Cell Surface Receptors
Endotoxins
Radioimmunoassay
Volunteers
Sepsis
Healthy Volunteers
Injections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Granowitz, E. V., Poutsiaka, D. D., Cannon, J. G., Wolff, S. M., Dinarello, C. A., Santos, A. A., & Wilmore, D. W. (1991). Production of interleukin-1-receptor antagonist during experimental endotoxaemia. The Lancet, 338(8780), 1423-1424. https://doi.org/10.1016/0140-6736(91)92725-H

Production of interleukin-1-receptor antagonist during experimental endotoxaemia. / Granowitz, E. V.; Poutsiaka, D. D.; Cannon, Joseph Gerard; Wolff, S. M.; Dinarello, C. A.; Santos, A. A.; Wilmore, D. W.

In: The Lancet, Vol. 338, No. 8780, 07.12.1991, p. 1423-1424.

Research output: Contribution to journalArticle

Granowitz, EV, Poutsiaka, DD, Cannon, JG, Wolff, SM, Dinarello, CA, Santos, AA & Wilmore, DW 1991, 'Production of interleukin-1-receptor antagonist during experimental endotoxaemia', The Lancet, vol. 338, no. 8780, pp. 1423-1424. https://doi.org/10.1016/0140-6736(91)92725-H
Granowitz EV, Poutsiaka DD, Cannon JG, Wolff SM, Dinarello CA, Santos AA et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. The Lancet. 1991 Dec 7;338(8780):1423-1424. https://doi.org/10.1016/0140-6736(91)92725-H
Granowitz, E. V. ; Poutsiaka, D. D. ; Cannon, Joseph Gerard ; Wolff, S. M. ; Dinarello, C. A. ; Santos, A. A. ; Wilmore, D. W. / Production of interleukin-1-receptor antagonist during experimental endotoxaemia. In: The Lancet. 1991 ; Vol. 338, No. 8780. pp. 1423-1424.
@article{92107d819ee2421188fc9a147fff1eae,
title = "Production of interleukin-1-receptor antagonist during experimental endotoxaemia",
abstract = "Interleukin-1 (IL-1) has been implicated in the pathogenesis of sepsis. IL-1-receptor antagonist (IL-1ra) is a naturally occurring inhibitor of IL-1 activity that competes with IL-1 for occupancy of cell-surface receptors but possesses no agonist activity. We induced endotoxaemia in 9 healthy human volunteers by injection of Escherichia coliendotoxin, and measured plasma concentrations of IL-1 and IL-1ra by radioimmunoassay during the next 24 h. Peak plasma concentrations of IL-1ra were about a hundred-fold greater than those of IL-1β. No IL-1 or IL-1ra were detectable in the plasma of 4 volunteers injected with saline. Our results suggest that the predominant natural response to endotoxin in man is the production of antagonist rather than agonist.",
author = "Granowitz, {E. V.} and Poutsiaka, {D. D.} and Cannon, {Joseph Gerard} and Wolff, {S. M.} and Dinarello, {C. A.} and Santos, {A. A.} and Wilmore, {D. W.}",
year = "1991",
month = "12",
day = "7",
doi = "10.1016/0140-6736(91)92725-H",
language = "English (US)",
volume = "338",
pages = "1423--1424",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8780",

}

TY - JOUR

T1 - Production of interleukin-1-receptor antagonist during experimental endotoxaemia

AU - Granowitz, E. V.

AU - Poutsiaka, D. D.

AU - Cannon, Joseph Gerard

AU - Wolff, S. M.

AU - Dinarello, C. A.

AU - Santos, A. A.

AU - Wilmore, D. W.

PY - 1991/12/7

Y1 - 1991/12/7

N2 - Interleukin-1 (IL-1) has been implicated in the pathogenesis of sepsis. IL-1-receptor antagonist (IL-1ra) is a naturally occurring inhibitor of IL-1 activity that competes with IL-1 for occupancy of cell-surface receptors but possesses no agonist activity. We induced endotoxaemia in 9 healthy human volunteers by injection of Escherichia coliendotoxin, and measured plasma concentrations of IL-1 and IL-1ra by radioimmunoassay during the next 24 h. Peak plasma concentrations of IL-1ra were about a hundred-fold greater than those of IL-1β. No IL-1 or IL-1ra were detectable in the plasma of 4 volunteers injected with saline. Our results suggest that the predominant natural response to endotoxin in man is the production of antagonist rather than agonist.

AB - Interleukin-1 (IL-1) has been implicated in the pathogenesis of sepsis. IL-1-receptor antagonist (IL-1ra) is a naturally occurring inhibitor of IL-1 activity that competes with IL-1 for occupancy of cell-surface receptors but possesses no agonist activity. We induced endotoxaemia in 9 healthy human volunteers by injection of Escherichia coliendotoxin, and measured plasma concentrations of IL-1 and IL-1ra by radioimmunoassay during the next 24 h. Peak plasma concentrations of IL-1ra were about a hundred-fold greater than those of IL-1β. No IL-1 or IL-1ra were detectable in the plasma of 4 volunteers injected with saline. Our results suggest that the predominant natural response to endotoxin in man is the production of antagonist rather than agonist.

UR - http://www.scopus.com/inward/record.url?scp=0025786074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025786074&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(91)92725-H

DO - 10.1016/0140-6736(91)92725-H

M3 - Article

C2 - 1683422

AN - SCOPUS:0025786074

VL - 338

SP - 1423

EP - 1424

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8780

ER -